Healios

Healios will expand the possibilities of curing diseases by developing and supplying regenerative medicine products to enhance and further enrich quality of life, as part of the rapid development of regenerative medicine in the biotechnology revolution. Healios aims to collaborate with RIKEN, one of Japan's leading research institutions, to commercialize the world’s first hiPSC-derived RPE cell transplantation drug for AMD treatment. The purpose of this therapy is to promote the regeneration of retinal function, thereby improving visual function in patients with degenerative retinal diseases. The significance of the total funds raised strengthens the company’s momentum in utilizing Nobel Prize-winning hiPSC technology to develop therapeutics, demonstrating its unwavering commitment to achieving groundbreaking progress in the field of regenerative medicine.